<?xml version='1.0' encoding='UTF-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.4-0' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' date='2012-08-30' release='1.4' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.4-0 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.4/CERIF_1.4_0.xsd' sourceDatabase='http://eprints.gla.ac.uk'>
  <cfResPubl>
    <cfResPublId>5cc8426e-e4b0-5282-b076-4de325474ae7</cfResPublId>
    <cfResPublDate>2008-03-15</cfResPublDate>
    <cfNum>6</cfNum>
    <cfVol>180</cfVol>
    <cfStartPage>4323</cfStartPage>
    <cfEndPage>4329</cfEndPage>
    <cfISSN>
    </cfISSN>
    <cfURI>http://eprints.gla.ac.uk/id/eprint/66399</cfURI>
    <cfTitle cfLangCode='en_GB' cfTrans='o'>The role of sphingosine kinase in a murine model of allergic asthma</cfTitle>
    <cfAbstr cfLangCode='en_GB' cfTrans='o'>Asthma is an allergic disease characterized by chronic airway eosinophilia and pulmonary infiltration of lymphocytes, particularly of the Th2 subtype, macrophages and mast cells. Previous studies have shown a pivotal role for sphingosine kinase (SphK) on various proinflammatory cells, such as lymphocyte and eosinophil migration and mast cell degranulation. We therefore examined the roles of SphK in a murine model of allergic asthma. In mice previously sensitized to OVA, i.p. administration of N,N-dimethylsphingosine (DMS), a potent SphK inhibitor, significantly reduced the total inflammatory cell infiltrate and eosinophilia and the IL-4, IL-5, and eotaxin levels in bronchoalveolar lavage fluid in response to inhaled OVA challenge. In addition, DMS significantly suppressed OVA-induced inflammatory infiltrates and mucus production in the lungs, and airway hyperresponsiveness to methacholine in a dose-dependent manner. OVA-induced lymphocyte proliferation and IL-4 and IL-5 secretion were reduced in thoracic lymph node cultures from DMS-treated mice. Moreover, similar reduction in inflammatory infiltrates, bronchoalveolar lavage, IL-4, IL-5, eotaxin, and serum OVA-specific IgE levels was observed in mice with SphK1 knock-down via small interfering RNA approach. Together, these data demonstrate the therapeutic potential of SphK modulation in allergic airways disease.</cfAbstr>
    <cfResPubl_Class>
      <cfClassId>journal_article</cfClassId>
      <cfClassSchemeId>class_scheme_publication_types</cfClassSchemeId>
    </cfResPubl_Class>
    <cfResPubl_Class>
      <cfClassId>published</cfClassId>
      <cfClassSchemeId>class_scheme_publication_state</cfClassSchemeId>
    </cfResPubl_Class>
    <cfResPubl_ResPubl>
      <cfResPublId2>3d01d4cd-2abd-58f4-b004-e7352b38f6eb</cfResPublId2>
      <cfClassId>part</cfClassId>
      <cfClassSchemeId>class_scheme_publication_publication_roles</cfClassSchemeId>
    </cfResPubl_ResPubl>
    <cfResPubl_Class>
      <cfClassId>yes</cfClassId>
      <cfClassSchemeId>class_scheme_publication_peer-reviewed</cfClassSchemeId>
    </cfResPubl_Class>
    <cfPers_ResPubl>
      <cfPersId>dd0df53e-0e51-5e9a-902d-39db56294b76</cfPersId>
      <cfClassId>creator</cfClassId>
      <cfClassSchemeId>class_scheme_person_publication_roles</cfClassSchemeId>
    </cfPers_ResPubl>
    <cfProj_ResPubl>
      <cjProjId>9817f4e7-8c5d-5040-b765-57e797b44a22</cjProjId>
    </cfProj_ResPubl>
    <cfPers_ResPubl>
      <cfPersId>e78295d5-81a0-5551-9371-1373934fe40c</cfPersId>
      <cfClassId>author_numbered</cfClassId>
      <cfClassSchemeId>class_scheme_person_publication_roles</cfClassSchemeId>
      <cfFraction>1</cfFraction>
    </cfPers_ResPubl>
    <cfPers_ResPubl>
      <cfPersId>04141d5a-99b6-5956-a5c4-7570e127a709</cfPersId>
      <cfClassId>author_numbered</cfClassId>
      <cfClassSchemeId>class_scheme_person_publication_roles</cfClassSchemeId>
      <cfFraction>2</cfFraction>
    </cfPers_ResPubl>
    <cfPers_ResPubl>
      <cfPersId>186164ea-1d77-58bf-b59c-14c18f656fbb</cfPersId>
      <cfClassId>author_numbered</cfClassId>
      <cfClassSchemeId>class_scheme_person_publication_roles</cfClassSchemeId>
      <cfFraction>3</cfFraction>
    </cfPers_ResPubl>
    <cfPers_ResPubl>
      <cfPersId>7cf57da2-3cf4-56e6-9439-150e18be100c</cfPersId>
      <cfClassId>author_numbered</cfClassId>
      <cfClassSchemeId>class_scheme_person_publication_roles</cfClassSchemeId>
      <cfFraction>4</cfFraction>
    </cfPers_ResPubl>
    <cfPers_ResPubl>
      <cfPersId>ddfdacc5-4a03-5d9a-a648-b9dd407156be</cfPersId>
      <cfClassId>author_numbered</cfClassId>
      <cfClassSchemeId>class_scheme_person_publication_roles</cfClassSchemeId>
      <cfFraction>5</cfFraction>
    </cfPers_ResPubl>
    <cfPers_ResPubl>
      <cfPersId>2608b135-680e-5e53-9fd8-8e93be88f0d4</cfPersId>
      <cfClassId>author_numbered</cfClassId>
      <cfClassSchemeId>class_scheme_person_publication_roles</cfClassSchemeId>
      <cfFraction>6</cfFraction>
    </cfPers_ResPubl>
  </cfResPubl>
  <cfPers>
    <cfPersId>dd0df53e-0e51-5e9a-902d-39db56294b76</cfPersId>
    <cfPersName>
      <cfFamilyNames>Wilkie</cfFamilyNames>
      <cfFirstNames>Laura</cfFirstNames>
    </cfPersName>
    <cfPers_EAddr>
      <cfClassId>email</cfClassId>
      <cfClassSchemeId>class_scheme_eaddress_types</cfClassSchemeId>
      <cfEAddrId>Laura.Wilkie@FAKEEMAIL</cfEAddrId>
    </cfPers_EAddr>
  </cfPers>
  <cfPers>
    <cfPersId>e78295d5-81a0-5551-9371-1373934fe40c</cfPersId>
    <cfPersName>
      <cfFamilyNames>Lai</cfFamilyNames>
      <cfFirstNames>W.Q.</cfFirstNames>
    </cfPersName>
  </cfPers>
  <cfPers>
    <cfPersId>04141d5a-99b6-5956-a5c4-7570e127a709</cfPersId>
    <cfPersName>
      <cfFamilyNames>Goh</cfFamilyNames>
      <cfFirstNames>H.H.</cfFirstNames>
    </cfPersName>
  </cfPers>
  <cfPers>
    <cfPersId>186164ea-1d77-58bf-b59c-14c18f656fbb</cfPersId>
    <cfPersName>
      <cfFamilyNames>Bao</cfFamilyNames>
      <cfFirstNames>Z.</cfFirstNames>
    </cfPersName>
  </cfPers>
  <cfPers>
    <cfPersId>7cf57da2-3cf4-56e6-9439-150e18be100c</cfPersId>
    <cfPersName>
      <cfFamilyNames>Wong</cfFamilyNames>
      <cfFirstNames>F.</cfFirstNames>
    </cfPersName>
  </cfPers>
  <cfPers>
    <cfPersId>ddfdacc5-4a03-5d9a-a648-b9dd407156be</cfPersId>
    <cfPersName>
      <cfFamilyNames>Melendez Romero</cfFamilyNames>
      <cfFirstNames>A.J.</cfFirstNames>
    </cfPersName>
    <cfPers_EAddr>
      <cfEAddrId>Alirio.Melendez-Romero@FAKEEMAIL</cfEAddrId>
    </cfPers_EAddr>
  </cfPers>
  <cfPers>
    <cfPersId>2608b135-680e-5e53-9fd8-8e93be88f0d4</cfPersId>
    <cfPersName>
      <cfFamilyNames>Leung</cfFamilyNames>
      <cfFirstNames>B.P.</cfFirstNames>
    </cfPersName>
    <cfPers_EAddr>
      <cfEAddrId>Bernard.Leung@FAKEEMAIL</cfEAddrId>
    </cfPers_EAddr>
  </cfPers>
  <cfResPubl>
    <cfResPublId>3d01d4cd-2abd-58f4-b004-e7352b38f6eb</cfResPublId>
    <cfISSN>0022-1767</cfISSN>
    <cfTitle cfLangCode='en_GB' cfTrans='o'>Journal of Immunology</cfTitle>
    <cfResPubl_Class>
      <cfClassId>journal</cfClassId>
      <cfClassSchemeId>class_scheme_publication_types</cfClassSchemeId>
    </cfResPubl_Class>
  </cfResPubl>
  <cfProj>
    <cfProjId>9817f4e7-8c5d-5040-b765-57e797b44a22</cfProjId>
    <cfProj_Fund>
      <cfFundId>9817f4e7-8c5d-5040-b765-57e797b44a22</cfFundId>
    </cfProj_Fund>
  </cfProj>
  <cfFund>
    <cfFundId>9817f4e7-8c5d-5040-b765-57e797b44a22</cfFundId>
    <cfAcro>G0700794</cfAcro>
  </cfFund>
</CERIF>
